Painful hands and feet after cancer treatment: Inflammation affecting the mind-body connection

Journal of Clinical Oncology

Volumn 34, Issue 7, 2016, Pages 649-652

  Ganz, Patricia A ^a   Dougherty, Patrick M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; VINCA ALKALOID;

BRAIN FUNCTION; BRAIN PERFUSION; BREAST CANCER; CALCIUM SIGNALING; CANCER ADJUVANT THERAPY; CANCER SURVIVOR; CANCER THERAPY; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CHRONIC PAIN; CINGULATE GYRUS; COGNITION; COGNITIVE DEFECT; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DRUG INDUCED DISEASE; EXECUTIVE FUNCTION; FATIGUE; FOOT PAIN; FRONTAL LOBE; GRAY MATTER; HAND PAIN; HOST SUSCEPTIBILITY; HUMAN; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PARESTHESIA; PARIETAL LOBE; PERIPHERAL NEUROPATHY; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; SPINAL GANGLION; SUPERIOR FRONTAL GYRUS; BRAIN CIRCULATION; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; NEUROTOXICITY SYNDROMES;

BREAST NEOPLASMS; CEREBROVASCULAR CIRCULATION; FEMALE; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROTOXICITY SYNDROMES; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84964319431     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.7479     Document Type: Review

References (40)

1. Hershman DL, Lacchetti C, Dworkin RH, et al: American Society of Clinical Oncology: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941-1967, 2014
2. Seretny M, Currie GL, Sena ES, et al: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and metaanalysis. Pain 155:2461-2470, 2014
3. Schneider B, Hershman D, Loprinzi C: Symptoms: Chemotherapy-induced peripheral neuropathy, in Ganz PA (ed): Improving Outcomes for Breast Cancer Survivors: Advances in Experimental Medicine and Biology, Cham, Switzerland, Springer International Publishing, 2015, pp 77-87
4. Cleeland CS, Bennett GJ, Dantzer R, et al: Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 97:2919-2925, 2003
5. Lee BN, Dantzer R, Langley KE, et al: A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation 11:279-292, 2004
6. Miller AH, Ancoli-Israel S, Bower JE, et al: Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 26:971-982, 2008
7. Vichaya EG, Chiu GS, Krukowski K, et al: Mechanisms of chemotherapyinduced behavioral toxicities. Front Neurosci 9:131, 2015
8. Nudelman K N H, McDonald BC, Wang Y, et al: Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol 34:677-683, 2016
9. Carozzi VA, Canta A, Chiorazzi A: Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 596:90-107, 2015
10. [Erratum: Neurosci Lett 596:108, 2015]
11. Boyette-Davis JA, Walters ET, Dougherty PM: Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Manag 5:285-296, 2015
12. Kim JH, Dougherty PM, Abdi S: Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy. Gynecol Oncol 136:453-459, 2015
13. Basch E, Reeve BB, Mitchell SA, et al: Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:106, 2014
14. Dueck AC, Mendoza TR, Mitchell SA, et al: National Cancer Institute PRO-CTCAE Study Group: Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1:1051-1059, 2015
15. Basch E: The missing voice of patients in drug-safety reporting. N Engl J Med 362:865-869, 2010
16. McDonald BC, Conroy SK, Smith DJ, et al: Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: A replication and extension study. Brain Behav Immun 30:S117-S125, 2013
17. Nudelman K N H, Wang Y, McDonald BC, et al: Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: A prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9:e96713, 2014
18. Huang HQ, Brady MF, Cella D, et al: Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: A gynecologic oncology group study. Int J Gynecol Cancer 17:387-393, 2007
19. Ahles TA, Saykin AJ: Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192-201, 2007
20. Ahles TA, Root JC, Ryan EL: Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. J Clin Oncol 30:3675-3686, 2012
21. Seigers R, Schagen SB, Van Tellingen O, et al: Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav 7:453-459, 2013
22. Zhang H, Boyette-Davis JA, Kosturakis AK, et al: Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2inprimary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. J Pain 14:1031-1044, 2013
23. Li Y, Zhang H, Zhang H, et al: Toll-like receptor 4 signaling contributes to paclitaxel-induced peripheral neuropathy. J Pain 15:712-725, 2014
24. Xiao WH, Bennett GJ: Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain 153:704-709, 2012
25. Zhang H, Dougherty PM: Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. Anesthesiology 120:1463-1475, 2014
26. McDonald BC, Conroy SK, Ahles TA, et al: Gray matter reduction associated with systemic chemotherapy for breast cancer: A prospective MRI study. Breast Cancer Res Treat 123:819-828, 2010
27. Pomykala KL, de Ruiter MB, Deprez S, et al: Integrating imaging findings in evaluating the post-chemotherapy brain. Brain Imaging Behav 7:436-452, 2013
28. Holohan KN, Von Ah D, McDonald BC, et al: Neuroimaging, cancer, and cognition: State of the knowledge. Semin Oncol Nurs 29:280-287, 2013
29. McDonald BC, Saykin AJ: Alterations in brain structure related to breast cancer and its treatment: Chemotherapy and other considerations. Brain Imaging Behav 7:374-387, 2013
30. Baliki MN, Apkarian AV: Nociception, pain, negative moods, and behavior selection. Neuron 87:474-491, 2015
31. Bower JE, Ganz PA, Irwin MR, et al: Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol 31:1656-1661, 2013
32. Aouizerat BE, Dodd M, Lee K, et al: Preliminary evidence of a genetic association between tumor necrosis factor alpha and the severity of sleep disturbance and morning fatigue. Biol Res Nurs 11:27-41, 2009
33. Miaskowski C, Dodd M, Lee K, et al: Preliminary evidence of an association between a functional interleukin-6 polymorphism and fatigue and sleep disturbance in oncology patients and their family caregivers. J Pain Symptom Manage 40:531-544, 2010
34. Illi J, Miaskowski C, Cooper B, et al: Association between pro- and antiinflammatory cytokine genes and a symptom cluster of pain, fatigue, sleep disturbance, and depression. Cytokine 58:437-447, 2012
35. Bower JE, Ganz PA, Irwin MR, et al: Inflammation and behavioral symptoms after breast cancer treatment: Do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol 29:3517-3522, 2011
36. Bower JE: Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 26:768-777, 2008
37. Ganz PA, Bower JE, Kwan L, et al: Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun 30:S99-S108, 2013
38. Pomykala KL, Ganz PA, Bower JE, et al: The association between proinflammatory cytokines, regional cerebral metabolism, and cognitive complaints following adjuvant chemotherapy for breast cancer. Brain Imaging Behav 7:511-523, 2013
39. Boyette-Davis JA, Eng C, Wang XS, et al: Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. Clin Cancer Res 18:3180-3187, 2012
40. Ahles TA: Brain vulnerability to chemotherapy toxicities. Psychooncology 21:1141-1148, 2012